Last reviewed · How we verify

NCT03129919

Arch Dimension and Inclination of the Upper and Lower Incisors Changes

Status unknown NA Last updated 26 April 2017
What this trial tests

NA trial testing Carriere SLX® (Passive self-ligating braces) in Malocclusion, Angle Class I in 60 participants. Status unknown.

Timeline
15 May 2017
Primary endpoint
1 April 2018
1 April 2018

Quick facts

Lead sponsorFundación Universitaria CIEO
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposetreatment
Enrollment60
Start date15 May 2017
Primary completion1 April 2018
Estimated completion1 April 2018

Drugs / interventions tested

Conditions studied

Sponsor

Fundación Universitaria CIEO

Who can join

Adults 16 to 35, any sex, with Malocclusion, Angle Class I. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

It is intended to evaluate changes in arch dimensions and incisor inclination as well as changes in the WALA Ridge in no extraction patients treated with interactive self-ligating brackets (Empower®) and passive (Carriere SLX®) at the end of the phase of alignment and leveling. For this, study models and profile radiographs taken before the start of treatment and at the end of the alignment and leveling phase will be evaluated. The parameters to be measured are: intercanine distance, arch depth, upper and lower incisor inclination, and WALA ridge analysis

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Malocclusion, Angle Class I

Currently open trials in the same condition.

Other Fundación Universitaria CIEO trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03129919.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing